x.com· @ · X·· 2026-04-22Score60
Reading
Next-generation ADCs: payload innovation
AVA6103 / pan-RAS ADC · Tricomplex pan-RAS as payload
Body
In this video presentation, the Avacta team discuss the AVA6103 (FAP-EXd) preclinical and clinical trial in progress highlights presented at this week’s #AACR26 Annual Meeting. https://t.co/j5p34QJjhH
(A second presentation will be coming soon!) #AVCT
Heat 169 · 148 likes · 0 replies · 21 reposts
Conference abstracts
5846matched by 代号 AVA6103
AVA6103 is a FAP-enabled pre|CISION®peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activityCurtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Francis Wilson, Michelle Morrow
Read the abstract →Source: x.com · x.com